Novavax has issued a clarification regarding an analyst report published on October 1, 2024, which referenced discussions about the anticipated U.S. COVID-19 vaccination market for 2024-2025. The company emphasized that while it expects the U.S. COVID-19 vaccination market to be similar to last year, it has neither updated nor reaffirmed its full year 2024 financial guidance that was previously issued on August 8, 2024.The company's statement comes amid its ongoing partnership with Sanofi Pasteur for the 2024-2025 vaccination season, which involves technology transfers and manufacturing transitions. Novavax is working on implementing its updated 2024-2025 formula COVID-19 vaccine, available in both single-dose vial and pre-filled syringe presentations, while pursuing Biologics License Application approval from the FDA.

Novavax has issued a clarification regarding an analyst report published on October 1, 2024, which referenced discussions about the anticipated U.S. COVID-19 vaccination market for 2024-2025. The company emphasized that while it expects the U.S. COVID-19 vaccination market to be similar to last year, it has neither updated nor reaffirmed its full year 2024 financial guidance that was previously issued on August 8, 2024.The company's statement comes amid its ongoing partnership with Sanofi Pasteur for the 2024-2025 vaccination season, which involves technology transfers and manufacturing transitions. Novavax is working on implementing its updated 2024-2025 formula COVID-19 vaccine, available in both single-dose vial and pre-filled syringe presentations, while pursuing Biologics License Application approval from the FDA.